Graftys Announces Creation of an International Implant Registry to Follow up Graftys® HBS and Graftys® QuickSet
GRAFTYS SA, a company which develops and commercializes biomaterials used in orthopedic surgery, announces that it has recently established an ambitious Post Marketing Surveillance program, in the form of an internationally based registry of patients who have received implants of GRAFTYS® HBS et GRAFTYS® QuickSet. Both of these advanced phosphocalcic cements are highly injectable and resorbable.
This registry will put into practice «evidence-based medicine », which is highly applicable in the medical device industry and is being prioritized by government health authorities throughout the world. The goal is to systematically validate short term and long term clinical results for implantable devices after product launch.
In addition, the registry will document clinical results for recently approved innovative applications of GRAFTYS® HBS et GRAFTYS® QuickSet. Thanks to their high injectability, GRAFTYS cements can be used in numerous applications, such as bone marrow lesions (BML) in the knee, which was recently approved in Europe.
«It is important to be able to follow our patients over the middle and long term » states Pr. Sébastien Parratte, from the Institute of Movement and Locomotion (IML), at Hôpital de La Timone, Marseille, France, and coordinator of the GRAFTYS registry. «Three centers are currently participating in the program, and data from the first patients have already been included in France. »
« Discussions with additional international centers are underway to join the program » reports Jean-Marc Ferrier, Graftys’ Director of Regulatory and Clinical Affairs. « This registry will allow us to follow the long term outcomes for patients treated in about 20 centers and will thus become one of the most important registries in the field of injectable bone substitutes. Our plan is to use this data for publication in clinical journals. »
About GRAFTYS® HBS
GRAFTYS® HBS is a phosphocalcic apatitic cement, highly injectible and well adapted to the needs of minimally invasive implant procedures. The patented formula includes a resorbable polymer which permits the cement to offer superior injectability and high resorbability.
About GRAFTYS® Quickset
GRAFTYS® Quickset, which has a composition similar to that of GRAFTYS® HBS, provides a faster setting time, high cohesiveness, and a higher resistance to compressive force.
Abput GRAFTYS SA
Established in 2005 in France (Aix-en-Provence and Nantes), GRAFTYS has an office in the United States (Chicago). The company develops, manufactures and commercializes bioactive, synthetic biomaterials for orthopedics. GRAFTYS’ technologies provide innovative therapeutic solutions in the field of bone tissue engineering. The company has partnerships with the key public academic research institutions in France and is co-owner of several patents filed jointly with these partners. GRAFTYS has obtained clearance of three 510(k) applications from the FDA for its biomaterials using calcium phosphate, products which also have CE approval. GRAFTYS’ technologies provide treatment options for numerous indications in surgical applications in spine, orthopedics, trauma, and dental. GRAFTYS products are sold in more than 20 countries, including the United States, by specialized distributors.
For further information: http://www.graftys.com
Jean-Marc Ferrier, 04 42 60 30 00
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
LOXAM20.7.2018 16:53 | pressemeddelelse
Loxam Announces a Conditional Agreement to Acquire UK Platforms
SCHLUMBERGER-LIMITED20.7.2018 13:02 | pressemeddelelse
Schlumberger Announces Second-Quarter 2018 Results
FL-H.I.G.-CAPITAL19.7.2018 21:52 | pressemeddelelse
H.I.G. Capital Announces the Sale of KidsFoundation
SIG-COMBIBLOC-GROUP19.7.2018 18:03 | pressemeddelelse
SIG Combibloc Group Holdings S.à r.l.: 2018 Second Quarter Results
FL-NEORIS19.7.2018 17:34 | pressemeddelelse
NEORIS Announces Creation of Innovation Labs Worldwide to Create a Smarter Future
CQN-FLEXTRADE19.7.2018 17:31 | pressemeddelelse
CORRECTING and REPLACING Albar Capital Deploys FlexNOW
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum